Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease-Reference-Cited by-同舟云学术

Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease

Published:2019-12-12 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Davies Sarah C¹,Nguyen Tran M²,Parker Claire E²,MacDonald John K³,Jairath Vipul²³⁴,Khanna Reena²³

Affiliation:

1. University of Western Ontario; Schulich School of Medicine & Dentistry; London ON Canada

2. Robarts Clinical Trials; 100 Dundas Street, Suite 200 London ON Canada

3. University of Western Ontario; Department of Medicine; London ON Canada

4. University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012804.pub2/epdf/full

Reference99 articles.

1. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 studies;Adedokun;Journal of Crohn's and Colitis,2016

2. Exposure-response to SC ustekinumab in moderate-severe Crohn's disease: results from the IM-UNITI maintenance study;Adedokun;United European Gastroenterology Journal,2017

3. Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies;Adedokun;Gastroenterology,2016

4. Response and remission after 16 weeks of ustekinumab-an all patients analysis from the UNITI Crohn's studies;Colombel;United European Gastroenterology Journal,2017

5. Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies;Colombel;Journal of Crohn's and Colitis,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis;Biomedicines;2023-12-06

3. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease;Cureus;2023-10-11

4. The role of Th17 cells in inflammatory bowel disease and the research progress;Frontiers in Immunology;2023-01-09

5. Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials;Central European Journal of Immunology;2023